Pursuant to the Licensing Agreement, Kintor Pharma will receive from Etana upfront and milestone payments, in addition to the economic benefit relating to the sales from the launch of proxalutamide in Indonesia, which is in line with the industry practice.

Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, "We are excited to establish a strategic collaboration with Etana. Recently, the highly contagious Delta strain of COVID-19 variant has been reported in many countries around the world, including Indonesia. In collaboration with Etana, we believe that proxalutamide will serve as an important tool in the fight against COVID-19 pandemic in Indonesia."

Mr. Nathan Tirtana, Co-founder and CEO of Etana, commented, "We felt the collaboration with Kintor Pharma is very important to fight against the pandemic of COVID-19. We hope the collaboration will help the governments to give a better treatment for COVID-19 patients in Indonesia as proxalutamide has demonstrated impressive clinical efficacy and safety in other countries clinical trials for the treatment of COVID-19 infection."